Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.

ABSTRACT:

Background

HER2-positive or ERBB2 amplified (ERBB2 amp+) metastatic colorectal cancer (mCRC) is an important subgroup due to emerging HER2-targeted therapies. Although ERBB2 amplification is associated with anti-EGFR antibody resistance, optimal first-line treatment remains unclear.

Methods

We analysed data from the Flatiron Health-Foundation Medicine CRC clinico-genomic database, including patients with stage IV or recurrent mCRC diagnosed between January 2012 and March 2022 who underwent tissue-based comprehensive genomic profiling. ERBB2 amp+ was defined as an ERBB2 copy number ≥+3 of the tumour base ploidy.

Results

Among 5545 patients, 144 (3.1%) had ERBB2 amp+ mCRC. These patients showed significantly worse real-world progression-free survival (rwPFS) than ERBB2

SUBMITTER: Matsubara Y 

PROVIDER: S-EPMC12852667 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature